Loading patent…
AssigneesElan Pharmaceuticals, Inc., Wyeth
InventorsAndrei W. Konradi, Christopher M. Semko, Ying-zi Xu, Frank Stappenbeck, Brian P. Stupi, Jenifer L. Smith, Michael A. Pleiss, Eugene D. Thorsett
Estimating the term…
Disclosed are compounds which bind α4 integrins, where the α4 integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4 integrins, where the α4 integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
A compound of formula (I):
A compound of Formula II:
A compound of Formula III:
A compound selected from the group consisting of:
A compound of formula (IV):
A compound of Formula V:
A compound of Formula VI:
A compound selected from the group consisting of:
Dependencies are inferred from the claim text.